Feng Zhang
Capital Medical University
5 Papers
1 Citations
Feng Zhang is an academic researcher from Capital Medical University. The author has contributed to research in topics: Macular edema & Pro re nata. The author has an hindex of 3, co-authored 5 publications. Previous affiliations of Feng Zhang include Beijing Tongren Hospital.
Chat about Author
Papers
A 50% vs 30% Dose of Verteporfin (Photodynamic Therapy) for Acute Central Serous Chorioretinopathy: One-Year Results of a Randomized Clinical Trial
Mingwei Zhao,Feng Zhang,Youxin Chen,Hong Dai,Jinfeng Qu,Jinfeng Qu,Chongya Dong,Xiaoping Kang,Yuling Liu,Liu Yang,Yibin Li,Peng Zhou,Peng Zhou,Chungting Pan,Chungting Pan,Lijuan Zhang,Lijuan Zhang,Peipei Liu,Peipei Liu,Hai-ying Zhou,Xuan Jiao,Ying Xiong,Rong Tian,Yingyi Lu,Xiaobing Yu,Xiaoxin Li,Xiaoxin Li +26 more
TL;DR: A 50% dose of verteporfin may be more effective at resolving subretinal fluid and fluorescein leakage, and with better visual outcomes, than a 30% dose for acute central serous chorioretinopathy.
62
Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion.
Zuhua Sun,Haiying Zhou,Bing Lin,Xuan Jiao,Yingdong Luo,Feng Zhang,Shanshan Tao,Quan Wu,Zunhong Ke,Xiaoling Liu +9 more
TL;DR: Intravitreal injections of conbercept demonstrated a generally favorable safety and tolerability profile as well as efficacy in the treatment of macular edema due to RVO.
58
Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion.
TL;DR: The numbers of HF in ORL are prognostic factors associated with the final BCVA in patients with ME due to RVO after anti-VEGF treatment, and are associated with poor visual outcome among three groups.
47
Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.
Kun Liu,H.D. Wang,Wei He,Jian Ye,Yanping Song,Yusheng Wang,Xiaoling Liu,Zhifeng Wu,Shaojun Chen,Ke Fan,Yuling Liu,Feng Zhang,Feng Zhang,Zhiqing Li,Lin Liu,Junjun Zhang,Xue-Dong Zhang,Junjie Ye,Xiaoling Liang,Xiaoxin Li,Xiao Ke,Quan Wu,Jie Li,Shanshan Tao,Xinguo Wang,Philip J. Rosenfeld,Jeffrey S. Heier,Peter K. Kaiser,Xun Xu +28 more
TL;DR: In this article, the efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation in the treatment of diabetic macular oedema (DME) were demonstrated.
38
Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China.
Jian Ming,Yabing Zhang,Xun Xu,Mingwei Zhao,Yusheng Wang,Youxin Chen,Feng Zhang,Jiawei Wang,Jun Liu,Xinran Zhao,Rong Han,Shanlian Hu +11 more
TL;DR: Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation and ranibizumab; it was considered in a 20-year horizon as a dominant strategy whenCompared with ranibzumab.
5